Fig. 2

Pathologic complete response (pCR) rate according to neoadjuvant treatment regimens stratified by stromal tumor-infiltrating lymphocytes (sTILs): (A) in lymphocyte-predominant breast cancer (LPBC) with high sTILs (≥ 50%), and (B) in non-LPBC with low sTILs (< 50%)